Prof. Dr. Mehmet Hilmi Doğu
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
COVID-19 6 publicationsSource: OpenAlex / PubMed MeSHView publications
- Leukemia, Lymphocytic, Chronic, B-Cell 5 publications
- Lymphoma, Large B-Cell, Diffuse 5 publications
- Leukemia, Myeloid, Acute 4 publications
- Hodgkin Disease 4 publications
- Multiple Myeloma 3 publications
- Lymphoma, Non-Hodgkin 2 publications
- Pneumonia, Viral 2 publications
- Coronavirus Infections 2 publications
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 publications
- Lymphoma, T-Cell, Peripheral 2 publications
Person ↔ Disease
Which topics does this doctor work on?
Medical areas of interest the doctor lists on their own profile on the institution’s website. Source: livhospital.com.
- Lenfomalar (Hodgkin ve Non-Hodgkin Lenfomalar)
- Multiple Myeloma ve Plazma hücre hastalıkları
- Akut Lösemiler ( Akut Myeloblastik Lösemi / Akut Lenfoblastik Lösemi)
- Kronik Lösemiler (Kronik Lenfositer Lösemi/Kronik Myeloid Lösemi)
- Kronik Myeloproliferatif Hastalıklar (Polistemia Vera, Esansiyel Trombositoz, Myelofibrozis)
CV
Education and experience
Experience
- 2015Selçuk Üniversitesi Tıp Fakültesi Hastanesilivhospital.com
- 2016-2011Pamukkle Üniversitesi İç Hastalıkları Uzmanlık Eğitimilivhospital.com
- 2011-2011Denizli Sarayköy Devlet Hastanesilivhospital.com
- 2011-2014Pamukkle Üniversitesi Hematoloji Yandal Uzmanlık Eğitimilivhospital.com
- 2015-2020İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Kliniği Uzman Doktorlivhospital.com
- 2015-2020İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Kliniği İdari Sorumlusulivhospital.com
- 2019-2020İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Kliniği İdari Sorumlu/ Eğitim Görevlisilivhospital.com
- 2020-2020İstanbul Başakşehir Çam ve Sakura Şehir Hastanesi Hematoloji Kliniği Eğitim Görevlisilivhospital.com
Education
- 1999-2005Ege Üniversitesi Tıp Fakültesi Tıp Doktorulivhospital.com
- 2006-2011Pamukkale Üniversitesi İç Hastalıkları Uzmanılivhospital.com
- 2011-2014Pamukkale Üniversitesi Hematoloji Uzmanılivhospital.com
- 2014ESCCA Summer School On Cytometry/PRAG (Mayıslivhospital.com
- 2018İstanbul Eğitim ve Araştırma Hastanesi Hematoloji Doçentlivhospital.com
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyHaematologylivhospital.comFrom source
- InstitutionLiv Hospital Bahçeşehir, Liv Hospital Uluslivhospital.comFrom source
- Area of workCOVID-19Extracted from 6 publications · Model version —From source
- Publications125 publicationsORCID, OpenAlexFrom source
- ORCID0000-0001-7237-2637ORCIDFrom source
- Last synchronised4 November 2026 20:55https://www.livhospital.com/prof-dr-mehmet-hilmi-dogulivhospital.com
Scientific work
Publications on COVID-19
-
VEXAS Syndrome and IgG4-Related Disease: Coincidental Association or Pathogenetic Link?
Mediterranean journal of rheumatology, 2026
DOI 10.31138/mjr.230126.epr PMID 42100070 Open-access full textSource: ORCID
-
Follicular Lymphoma: Frequency and Timing of Treatment: Single Center Experience
Istanbul Medical Journal, 2025
DOI 10.4274/imj.galenos.2025.20788 Open-access full textSource: OpenAlex
-
Evaluation of The Relationship Between Bone Marrow Changes and Hemogram Findings in HIV-Positive Patients
Namık Kemal Tıp Dergisi, 2025
DOI 10.4274/nkmj.galenos.2025.29494 Open-access full textSource: OpenAlex
-
Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety
Indian Journal of Hematology and Blood Transfusion, 2025
DOI 10.1007/s12288-025-02093-w PMID 42040698 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
Acinetobacter baumannii in Hematology Practice: Clinical Factors Affecting the Course of Infection
Acta haematologica oncologica Turcica., 2024
DOI 10.4274/ahot.galenos.2024.2024-9-3 Open-access full textSource: OpenAlex
-
Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data
Hitit Medical Journal, 2024
DOI 10.52827/hititmedj.1320606 Open-access full textSource: OpenAlex
-
A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
Istanbul Medical Journal, 2023
DOI 10.4274/imj.galenos.2023.66742 1 citation (OpenAlex) Open-access full textSource: OpenAlex
-
AAT: does it have a place in acute leukemia?
Biomarkers in Medicine, 2023
DOI 10.2217/bmm-2023-0415 PMID 38197403 Source: ORCID
-
Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
Mediterranean Journal of Hematology and Infectious Diseases, 2023
DOI 10.4084/mjhid.2023.031 PMID 37180209 4 citations (Europe PMC) Open-access full textSource: ORCID
-
Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
Journal of Chemotherapy, 2023
DOI 10.1080/1120009x.2023.2208439 PMID 37211906 3 citations (Europe PMC) Source: ORCID